Recently the FDA approved a “Glowing Tumor” imaging drug to help oncologists better identify ovarian cancer cells using an approach pioneered by surgeons at Penn Medicine. Joining Dr. Charles Turck to discuss this recent approval and fluorescence-guided, intraoperative imaging is Dr. Janos Tanyi, Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania.